SG10202002557SA - Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment - Google Patents

Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Info

Publication number
SG10202002557SA
SG10202002557SA SG10202002557SA SG10202002557SA SG10202002557SA SG 10202002557S A SG10202002557S A SG 10202002557SA SG 10202002557S A SG10202002557S A SG 10202002557SA SG 10202002557S A SG10202002557S A SG 10202002557SA SG 10202002557S A SG10202002557S A SG 10202002557SA
Authority
SG
Singapore
Prior art keywords
peg
antibodies
cancer treatment
reduced cross
arginine deiminase
Prior art date
Application number
SG10202002557SA
Inventor
Robert Almassy
James A Thomson
Richard Showalter
Wes Sisson
Wei-Jong Shia
Li-Chang Chen
Yang Lee
Original Assignee
Tdw Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tdw Group filed Critical Tdw Group
Publication of SG10202002557SA publication Critical patent/SG10202002557SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006Arginine deiminase (3.5.3.6)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG10202002557SA 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment SG10202002557SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051182P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
SG10202002557SA true SG10202002557SA (en) 2020-04-29

Family

ID=55453727

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202002557SA SG10202002557SA (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
SG11201702103XA SG11201702103XA (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201702103XA SG11201702103XA (en) 2014-09-16 2015-09-16 Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment

Country Status (11)

Country Link
US (1) US9789170B2 (en)
EP (2) EP3193913B1 (en)
JP (2) JP6782230B2 (en)
KR (1) KR20170104986A (en)
CN (2) CN114522225A (en)
AU (1) AU2015317848B2 (en)
CA (1) CA2961602A1 (en)
ES (1) ES2915382T3 (en)
SG (2) SG10202002557SA (en)
TW (2) TWI708612B (en)
WO (1) WO2016044376A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
CN114522225A (en) 2014-09-16 2022-05-24 瑞华药业集团 Arginine deiminase with reduced cross-reactivity to ADI-PEG20 antibodies for cancer treatment
MX2019003475A (en) * 2016-09-29 2019-11-28 Meharry Medical College Bacterial inhibitors.
TW202308683A (en) * 2016-11-02 2023-03-01 開曼群島商北極星藥業集團股份有限公司 Formulations of pegylated arginine deiminase
TW201902935A (en) * 2017-03-29 2019-01-16 開曼群島商瑞華藥業集團 Protein conjugate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5804183A (en) 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US6180387B1 (en) 1997-08-11 2001-01-30 Smithkline Beecham Corporation Arginine deiminase
IT1298918B1 (en) 1998-02-20 2000-02-07 Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
WO2002009741A1 (en) 2000-07-27 2002-02-07 Angiolab, Inc. The pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
EP1337630A2 (en) 2000-11-28 2003-08-27 Phoenix Pharmacologics, Inc. Modified arginine deiminase
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
CN1536079A (en) * 2003-04-09 2004-10-13 上海复旦张江生物医药股份有限公司 Modified arginine deiminase
AU2004235382A1 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
WO2005052145A2 (en) 2003-10-07 2005-06-09 University Of Florida Recombinant alkaliizing bacteria
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
WO2010083312A2 (en) 2009-01-14 2010-07-22 The Trustees Of The University Of Pennsylvania Micro-rna biomarker in cancer
CN101591649B (en) * 2009-07-10 2013-02-13 江苏泰康生物医药有限公司 Methoxypolyethylene glycol-modified arginine deiminase, preparation thereof and use thereof
WO2011053871A2 (en) 2009-10-30 2011-05-05 Life Technologies Corporation Multi-primer assay for mycoplasma detection
CN101812438B (en) * 2010-03-25 2014-08-27 江苏泰康生物医药有限公司 Arginine deiminase mutant and preparation and application thereof
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
WO2012075173A2 (en) * 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US8663967B2 (en) 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
TW201735943A (en) 2012-04-04 2017-10-16 普拉瑞斯集團 Methods of treatment with arginine deiminase
WO2014151982A2 (en) 2013-03-15 2014-09-25 Polaris Group Arginine deiminase with reduced cross-reactivity toward adi – peg 20 antibodies for cancer treatment
WO2015143006A1 (en) 2014-03-18 2015-09-24 Tdw Group Engineered chimeric pegylated adi and methods of use
CN114522225A (en) 2014-09-16 2022-05-24 瑞华药业集团 Arginine deiminase with reduced cross-reactivity to ADI-PEG20 antibodies for cancer treatment

Also Published As

Publication number Publication date
JP2021004268A (en) 2021-01-14
TW201625295A (en) 2016-07-16
SG11201702103XA (en) 2017-04-27
ES2915382T3 (en) 2022-06-22
JP2017529366A (en) 2017-10-05
CN107073085A (en) 2017-08-18
TWI775160B (en) 2022-08-21
JP6782230B2 (en) 2020-11-11
TWI708612B (en) 2020-11-01
EP3193913A4 (en) 2018-07-18
EP3193913A1 (en) 2017-07-26
AU2015317848B2 (en) 2021-04-22
US9789170B2 (en) 2017-10-17
EP3193913B1 (en) 2022-05-11
KR20170104986A (en) 2017-09-18
WO2016044376A1 (en) 2016-03-24
CN107073085B (en) 2022-02-18
CN114522225A (en) 2022-05-24
CA2961602A1 (en) 2016-03-24
AU2015317848A1 (en) 2017-04-20
US20160074487A1 (en) 2016-03-17
EP4104853A1 (en) 2022-12-21
JP6961061B2 (en) 2021-11-05
TW202103730A (en) 2021-02-01

Similar Documents

Publication Publication Date Title
IL272572B (en) Antibody compositions for tumor treatment
HRP20201756T8 (en) Antibodies comprising modified heavy constant regions
HK1257775A1 (en) Tetravalent multispecific antibodies
ZA201605660B (en) Multispecific antibodies
PL3227332T3 (en) Multispecific antibodies
GB201414823D0 (en) Multispecific antibodies
HK1245804A1 (en) Anti-csf1r antibodies for treating pvns
HK1219232A1 (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment adi-peg 20
SG10202002557SA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
IL250507A0 (en) Anti-ck8 antibodies for use in the treatment of cancers
IL246558A0 (en) Novel methods for treating cancer
GB201413942D0 (en) Peptides useful for treating cancer